The GLP-1 tracker for the weeks that make people quit.

Dose AI is a free iOS app built specifically for GLP-1 users, rated 4.7 stars across 994 App Store ratings. It keeps injections, injection sites, food, side effects, hydration, and weight in one daily log, so you can see how a dose change lines up with how you actually felt and what you ate that week.

Yes. Dose AI is free to download and the core tracking — shots, food, water, symptoms, and weight — works without paying. Premium AI insights are available by subscription for people who want deeper personalization.

Most GLP-1 medications, including Ozempic, Wegovy, and Mounjaro, are injected once weekly on the same day each week. Your prescriber sets your schedule and dose. Dose AI tracks your injection schedule, rotates injection sites for you, and reminds you when the next shot is due.

Log the symptom with a severity rating as soon as it starts. Dose AI places it on the same timeline as your dose day, food, and water, which makes patterns easier to see — for example rougher days in the 48 hours after a dose increase. Bring that timeline to your clinician rather than adjusting your dose on your own.

Nausea and other side effects commonly improve within 4 to 8 weeks as your body adjusts, and often flare again briefly after each dose increase. Persistent or severe symptoms are worth raising with your prescriber. Dose AI helps you track when symptoms occur so you can describe the pattern accurately.

Dose AI tracks protein, fiber, calories, and water against daily goals suited to GLP-1 appetites. Photograph a meal and the AI food scanner identifies it and fills in the nutrition, which matters when portions shrink and every gram of protein has to count toward preserving muscle.

Many people find high-fat and greasy foods, very spicy foods, alcohol, and large portions worsen nausea and reflux. Tolerance is individual. Dose AI helps you log what you ate alongside how you felt, so you can identify your own triggers instead of guessing.

In clinical trials, semaglutide (Wegovy) averaged about 14.9% of body weight over 68 weeks in the STEP 1 trial, and tirzepatide (Zepbound) averaged about 20.9% at the highest studied dose in SURMOUNT-1. These are averages from separate trials, not head-to-head results, and individual outcomes vary widely.

Ozempic and Wegovy both contain semaglutide, a GLP-1 receptor agonist. Mounjaro and Zepbound both contain tirzepatide, which acts on both GLP-1 and GIP receptors. Within each pair, the difference is what the drug is approved to treat and the dosing — Ozempic and Mounjaro for type 2 diabetes, Wegovy and Zepbound for weight management.

Plateaus are common and can involve dose level, protein and calorie intake, sleep, muscle loss, or simply the body adjusting. Dose AI shows your weight trend against your dose history and food logs so you and your clinician can see which variable actually changed, rather than guessing.

Alcohol can worsen nausea, irritate the stomach, and affect blood sugar, and many people report a much lower tolerance on a GLP-1. Most clinicians advise limiting it. Ask yours about your situation, and use Dose AI to log how alcohol affects your own symptoms.

Increasing fiber and water intake and adding gentle movement helps most people. Dose AI tracks hydration against a daily target and shows fiber alongside protein and calories, so you can see whether you are actually hitting both. Talk to your clinician if it persists.